BC
ACOR

Broadfin Capital’s Acorda Therapeutics ACOR Stock Holding History

Broadfin Capital’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,368
Closed -$12.1M – 67
2016
Q4 		$12.1M Buy
5,368
+329
+7% +$782K 1.34% 22
2016
Q3 		$12.6M Buy
+5,039
New +$15M 1.13% 26

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.16B AUM 16.24% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital's ACOR Position: Q1 2017 in Review

Broadfin Capital sold out of Acorda Therapeutics (ACOR) in Q1 2017, closing a stake of 5,368 shares — an estimated $12.1M sold.

Broadfin Capital first reported a position in ACOR in Q3 2016 and held it in 2 quarters. The position peaked at $12.6M in Q3 2016. 178 funds tracked by Wall St. Rank hold ACOR as of Q1 2017.

  • Broadfin Capital reported no remaining Acorda Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Broadfin Capital sold 5,368 Acorda Therapeutics shares in Q1 2017, an estimated $12.1M.
  • Broadfin Capital first reported a position in Acorda Therapeutics in Q3 2016 and held it in 2 quarters.
  • Broadfin Capital's Acorda Therapeutics position peaked at $12.6M in Q3 2016.
  • 178 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2017.

Based on Broadfin Capital's 13F filing for Q1 2017, filed 15 May 2017.